Quince Therapeutics (QNCX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
Annual meeting scheduled for June 11, 2026, with voting open until June 10, 2026, at 11:59 PM ET.
Shareholders can access proxy materials online or request paper/email copies by May 28, 2026.
Virtual meeting access and in-person voting options are available, with specific instructions for legal proxy requests.
Voting matters and shareholder proposals
Election of June Bray as Class I director nominee to serve until the 2029 annual meeting.
Approval sought for a reverse stock split at a ratio between one-for-ten and one-for-one-hundred.
Ratification of BDO USA, P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote on executive compensation for named executive officers.
Approval to adjourn or postpone the meeting if further solicitation of proxies is needed.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director election and corporate actions.
Latest events from Quince Therapeutics
- Phase III EryDex trial in rare disease underway, with broad expansion and strong safety profile.QNCX
LD Micro Main Event XVII8 Jul 2026 - Phase 3 data show red blood cell-encapsulated dexamethasone slows AT decline in children 6–9.QNCX
Investor Update8 Jul 2026 - Phase III data for a chronic steroid therapy in rare disease expected Q4, with strong safety and efficacy.QNCX
The Citizens JMP Life Sciences Conference 20258 Jul 2026 - Phase 3 trial of monthly red blood cell-encapsulated steroid therapy for AT nears full enrollment.QNCX
Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 20258 Jul 2026 - eDSP phase III for AT completed enrollment; topline data due Q1 2026.QNCX
Investor Day 20258 Jul 2026 - Acquisition and up to $187M financing advance LAM-001 for rare lung diseases through 2028.QNCX
Investor update19 May 2026 - Inhaled LAM-001 improved functional class and key clinical endpoints with good tolerability.QNCX
Investor presentation18 May 2026 - Lead asset failed in Phase 3, triggering a $67.8M impairment and urgent need for new funding.QNCX
Q1 202611 May 2026 - Key votes include a reverse stock split, director election, and auditor ratification to support compliance.QNCX
Proxy filing27 Apr 2026